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Objective: People with schizophrenia show a high incidence of metabolic syndrome, which is associated
with a high mortality from cardiovascular disease. The aetiology of the metabolic syndrome in
schizophrenia is multi-factorial and may involve antipsychotic treatment, high levels of stress and
unhealthy lifestyle, such as poor diet. As a poor diet can predispose to the development of metabolic
abnormalities, the aims of this review are to clarify: 1) the dietary patterns of patients with schizophrenia,
2) the association of these dietary patterns with a worse metabolic proﬁle, and 3) the possible factors
inﬂuencing these dietary patterns.
Methods: A search was conducted on Pubmed, The Cochrane Library, Scopus, Embase, Ovid, Psychoinfo
and ISI web of Knowledge from 1950 to the 1st of November 2011. 783 articles were found through the
investigation of such databases. After title, abstract or full-text reading and applying exclusion criteria we
reviewed 31 studies on dietary patterns and their effects on metabolic parameters in schizophrenia.
Results: Patients with schizophrenia have a poor diet, mainly characterized by a high intake of saturated
fat and a low consumption of ﬁbre and fruit. Such diet is more likely to increase the risk to develop
metabolic abnormalities. Data about possible causes of poor diet in schizophrenia are still few and
inconsistent.
Conclusion: Subjects with schizophrenia show a poor diet that partly accounts for their higher incidence
of metabolic abnormalities. Further studies are needed to clarify the causes of poor diet and the role of
dietary intervention to improve their physical health.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Background
People with schizophrenia have a reduced life expectancy
compared to the general population, primarily because of prema-
ture cardiovascular disease (Bobes et al., 2010; Laursen, 2011;
Wahlbeck et al., 2011). This condition may be explained in terms
of a high rate of metabolic syndrome in these patients (Arango
et al., 2008), which carries with it a series of risk factors for
cardiovascular disease, such as central obesity, atherogenic dysli-
pidemia, hypertension, and impaired insulin and glucose metabo-
lism. Furthermore metabolic syndrome is also associated with an
elevated prothrombotic and proinﬂammatory state which may iniatry & Stress, Psychiatry and
f Behaviour, The James Black
on, 125 Coldharbour Lane,
: þ44 (0)20 7848 0986.
ndelli).
Y-NC-ND license.turn increase the mortality from cardiovascular disease (Hasnain
et al., 2010).
The mechanism underlying the increased prevalence of meta-
bolic syndrome in patients with schizophrenia is still unclear.
A number of explanations have been hypothesised: genetic
predisposition (Gough and O’Donovan, 2005), antipsychotic drug
action on metabolism and heart function (Stahl et al., 2009), alter-
ations of the hypothalamicepituitaryeadrenal axis activity due to
high levels of stress (Anagnostis et al., 2009), and unhealthy lifestyle
(Brown et al., 1999; Mushtaq et al., 2008). Some studies have re-
ported a greater likelihood of metabolic problems in ﬁrst-degree
relatives of patients with schizophrenia (Spelman et al., 2007),
and the presence of common susceptibility alleles for both schizo-
phrenia and diabetes (Gough and O’Donovan, 2005); however, the
genetic link between schizophrenia and metabolic problems has
still not been clearly elucidated and would need further investiga-
tion. In contrast, it is widely acknowledged that antipsychotic
treatment is associated with several metabolic side effects such as
weight gain, insulin and leptin resistance, glucose intolerance,
S. Dipasquale et al. / Journal of Psychiatric Research 47 (2013) 197e207198dyslipidemia and alterations of cardiac function (Stahl et al., 2009).
However, some studies have reportedmetabolic alterations, such as
abnormal glucose tolerance and increased fasting glucose, also in
drug naïve patients (Ryan et al., 2003). Indeed, investigating meta-
bolic abnormalities and dietary habits in ﬁrst episode psychosis is
particularly relevant as these studies are less likely to be biased by
effect of antipsychotic treatment and long duration of illness. The
ﬁndings of metabolic abnormalities in ﬁrst episode psychosis have
been hypothesised to be related to high levels of stress and the
consequent hyperactivity of the hypothalamicepituitaryeadrenal
axis. Indeed, high levels of stress in both childhood and adulthood
have been consistently reported in patients with psychosis (Fisher
et al., 2009; Laursen et al., 2007), and more recently at the time of,
or before, the onset of the ﬁrst psychotic episode (Aas et al., 2011;
Aiello et al., 2012; Belvederi Murri et al., 2012; Mondelli and
Pariante, 2010; Mondelli et al., 2010a,b; Pariante et al., 2004). The
hyperactivity of thehypothalamicepituitaryeadrenal axis enhances
circulating levels of cortisol and causes glucocorticoid resistance,
which in turn increase the deposit of visceral fat and cause alter-
ations of leptin signals, insulin resistance and glucose tolerance
(Anagnostis et al., 2009). Moreover, repeated episodes of psycho-
logical stress in both childhood and adulthoodmay induce a chronic
inﬂammatory process (Di Nicola et al., 2012; Mondelli and Pariante,
2010), characterized by increased inﬂammatory markers such as C-
reactive protein (CRP) (Hepgul et al., 2012), which in turn may
predispose to the development of metabolic abnormalities (Danese
et al., 2009). At the same time, the unhealthy lifestyle of patients
with schizophrenia may also play an important role in the devel-
opment ofmetabolic syndrome. These patients aremore likely to be
heavy smokers, have high rates of alcohol consumption and
substances abuse, and low levels of physical activity and poor diet
(Brown et al., 1999). Interestingly, it has been reported that diet is
a major and modiﬁable cause of cardiovascular disease, as a poor
diet may be strongly linked to insulin resistance, dyslipidemia and
hypertension. Past studies concerning eating habits in non-
psychiatric subjects have suggested a strong link between the
metabolic syndrome and the consumption of somemacro-nutrients
such as saturated and unsaturated fats, fruits, vegetables, sugar and
salt. Apart from the obvious association between high calories
intake and obesity, it has also been reported that a diet rich in high
saturated fats and poor in unsaturated fats is associated with
obesity, increased concentration of LDL cholesterol and insulin
resistance (Siri-Tarino et al., 2010). A high intake of carbohydrates,
especially reﬁned sugars with elevated Glycemic Load (GL), is
related to high fasting triglycerides and low HDL cholesterol levels
(Hu and Willett, 2002). A poor ﬁbre and fruit consumption is asso-
ciated with increased food intake and reduced control on glucose
homeostasis and plasma lipid levels (Delzenne and Cani, 2005).
Finally, high salt intake may have a key role in the development of
hypertension (Chen et al., 2010).Table 1
Methods.
Search engine Keywords
Pubmed (diet OR dietary OR nutrition OR nutritional OR e
AND (schizophrenia OR psychosis OR psychotic)
(lifestyle OR metabolic OR health habits)
The Cochrane Library The same as above
Scopus The same as above
Embase The same as above
Ovid of Medline The same as above
Psychoinfo The same as above
ISI web of knowledge
(conferencal and proceeding)
The same as above
Added from references
Total of reviewed papers: 31Therefore, given that diet may represent a key factor in the
development of metabolic syndrome, this paper aimed to review
studies on dietary habits in patients with schizophrenia-spectrum
disorders, to clarify whether these dietary patterns may be asso-
ciated with the development of metabolic syndrome, and under-
stand which factors may inﬂuence them.2. Materials and methods
We conducted a systematic review of the literature reviewing
studies in English language published from 1950 to the 1st of
November 2011, and reporting dietary habits in patients with
schizophrenia spectrum disorders, identiﬁed by searches on
Pubmed, The Cochrane Library, Scopus, Embase, Ovid of Medline,
Psychoinfo and ISI web of Knowledge. Search terms over full text
included the combination of the following keywords: DIET or
DIETARY or NUTRITION or NUTRITIONAL or EATING or FOOD,
crossed with SCHIZOPHRENIA or PSYCHOSIS or PSYCHOTIC and
with LIFESTYLE or METABOLIC or HEALTH HABITS. More than 700
articles (n ¼ 783, excluding duplicates) were found through the
investigation of such databases. After title, abstract or full-text
reading, we selected a total of 89 papers; after checking refer-
ences from these studies other 9 articles were added, obtaining
a total of 98 papers. Among these, we excluded papers focused on:
1) eating habits and their relationship with prevention, psycho-
pathology, treatment and outcome of schizophrenia (n ¼ 22); 2)
trials to improve dietary habits and manage weight gain (n ¼ 25);
3) reviews on dietary habits of patients with schizophrenia (n ¼ 3);
4) studies dealing with food habits of patients with schizophrenia,
which matched cases and controls for diet or did not provide any
information on the consumption of macro-nutrients or groups of
food (n ¼ 17). Eventually, we reviewed thirty-one (n ¼ 31) studies
concerning the dietary patterns and their effects on metabolic
parameters in patients with schizophrenia. Table 1 summarizes our
methods.3. Results
Most studies were focused on the assessment of unhealthy
lifestyle, metabolic abnormalities and cardiovascular risk in chronic
patients with schizophrenia. In the majority of the studies, the
results were compared with data from the general population,
instead of data from a matched control group. Four studies focused
on ﬁrst-episode psychosis patients (Hepgul et al., 2011; Ryan et al.,
2003, 2004; Samele et al., 2007); only few (n ¼ 10) papers reported
a detailed medication history. Results from papers focused on ﬁrst-
episode patients were usually concordant with those from studies
involving chronic patients. A summary of the details and ﬁndings of
the studies is shown in Table 2.Papers New selected papers
ating OR food)
AND
267 70 by title, 20 after abstract or full text reading
63 2 by title, none after abstract or full text reading
87 4 by title, 2 after abstract or full text reading
570 9 by title, 1 after abstract or full text reading
171 none
141 3 by title, none after abstract or full text reading
24 1 by title and after full text reading
9 7 after full text reading
Table 2
Characteristics of the studies.
Study Subjects Comparison Diet assessment Treatment Main ﬁndings Fat intake Fibre intake Fruit intake Other factors
Hepgul et al.,
2011
101 ﬁrst-episode
psychosis patients
101 matched controls DINE No info Patients with
childhood sexual
abuse had a lower
ﬁbre intake than
patients without
abuse
No differences Lower in patients
with sexual abuse
No differences None
Ryan et al.,
2003
26 ﬁrst-episode
patients
26 matched controls DINE Drug naïve Patients have
a signiﬁcant
increased saturated
fat intake
Higher in patients No differences No differences None
Ryan et al.,
2004
19 ﬁrst-episode
patients
19 matched controls DINE Drug naïve, then
treated for six
months with either
olanzapine or
risperidone
Patients have
increased saturated
fat intake and low
ﬁbre consumption.
The diet did not
change after the
treatment
Higher in patients Lower in patients No differences None
Samele et al.,
2007
89 ﬁrst-episode
patients
89 matched controls The Health and
Lifestyle
questionnaire
12 patients under
treatment. Further
information not
provided
No difference in
dietary pattern
after adjusting for
employment
No differences No differences No differences None
Amani, 2007 30 chronic patients 30 matched controls Semi-quantitative
food frequency FFD
No info Patients, especially
women, had
a worse dietary
pattern
Higher in male
patients than male
controls
Lower in female
patients than
female controls
Lower in female
patients than
female controls
None
Arango et al.,
2008
1704 chronic
patients, divided
into two groups
(patients with and
without metabolic
syndrome)
None Eating habits
assessed by a series of
verbal questions
At least 12 weeks
treatment with only
one between
risperidone,
olanzapine,
quetiapine,
ziprasidone,
amisulpride,
haloperidol
Patients without
metabolic
syndrome are more
likely to avoid
saturated fats, to
control salt intake
and to follow a diet
Higher in patients
without metabolic
syndrome
No differences Not reported Higher salt intake
in patients without
metabolic
syndrome
Archie et al.,
2007
101 chronic
patients
Data from S. Francisco
Bay sample
Dietary Fat screener
and Fibre screener
Risperidone (29),
olanzapine (26),
clozapine (16),
combination (15),
ﬁrst generation
antipsychotic (15)
Patients’ diet was
too high in fat but
was better for fruit
and vegetable
intake than
controls
Higher in patients,
especially in
women
Higher in patients,
especially in men
Higher in patients None
Blouin et al.,
2008
18 chronic male
patients
20 matched controls A buffet composed of
a variety of foods was
offered to
participants to assess
diet
Clozapine (2),
olanzapine (9)
risperidone (2),
quetiapine (3),
ziprasidone (2)
No signiﬁcant
differences were
observed between
the two groups
No differences No differences No differences None
Bobes et al.,
2010
1704 chronic
patients
Data from general
population
Eating habits
assessed through
a series of verbal
questions
Most patients under
treatment. Further
information not
provided
Smokers patients
are more likely to
use salt, saturated
fat and are less
likely to follow
a high-ﬁbre and
low-caloric diet
Higher in smokers Lower in smokers No differences Higher salt intake
in smokers
Brown et al.,
1999
102 chronic
patients
Data from general
population
DINE Most patients under
treatment. Further
The subjects ate
a diet higher in fat
and lower in ﬁbre.
Higher in patients Lower in patients No differences None
(continued on next page)
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Table 2 (continued )
Study Subjects Comparison Diet assessment Treatment Main ﬁndings Fat intake Fibre intake Fruit intake Other factors
information not
provided
Chuang et al.,
2008
61 chronic patients
with schizophrenia,
60 with bipolar
disorder and 61
with depression
None Fat screener
questionnaire by
Block et al. and a 14-
item dietary
assessment
questionnaire by
Turconi et al.
Olanzapine (54),
risperidone (37),
quetiapine (32),
clozapine (10), typical
antipsychotic (19)
No differences
between the three
groups of patients
No differences Not assessed Not assessed None
DeMyer et al.,
1968
11 children
diagnosed with
schizophrenia or
autism
4 matched controls The daily food intake
was recorded for 20
consecutive days
No info Children with
schizophrenia
consumed more
calories than
healthy children
No differences No differences No differences Higher caloric
intake in children
with schizophrenia
Ellingrod et al.,
2011
63 chronic patients
treated with an
atypical
antipsychotic and
20 treated with
a ﬁrst generation
antipsychotic or
aripiprazole or
ziprasidone
None A 24 h diet recall Risperidone/
pailperidone (20),
clozapine (18),
quetiapine (14),
olanzapine (10),
aripiprazole (6),
ziprasidone (4)
No differences in
macronutrient and
caloric intake
between the two
groups of patients
No differences No differences No differences None
Fusar-Poli et al.,
2009
123 chronic
patients
None Use of fruit and
vegetables assessed
as “number per day”
No info Patients consume
2.24 portions of
fruit per day
compared to the
recommended 5
portions per day
Not assessed Lower than
recommended
Lower than
recommended
None
Gothelf et al.,
2002
20 adolescent
patients with
schizophrenia
None Food intake
monitored and
recorded for 2
consecutive days.
10 haloperidol-
treated patients and
10 olanzapine-
treated patients
Olanzapine-
induced weight
gain is associated
with a general
increase in caloric
intake
Not reported Not reported Not reported Increased caloric
intake in patients
under olanzapine
Gupta and
Craig, 2009
69 chronic patients Data from general
population
Food frequency
questionnaire
No info Patients consumed
signiﬁcantly less
ﬁbre and fruit
No differences Lower in patients Lower in patients None
Henderson
et al., 2005
15 chronic patients 9 matched controls 4 day dietary record
according to Reed
and Burke (1954)
7 quetiapine-treated
patients and 8
olanzapine-treated
patients
Patients and
controls did not
differ in
macronutrients
intake
No differences No differences No differences None
Henderson
et al., 2006
88 chronic patients Data from general
population
4 day dietary record
according to Reed
and Burke (1954)
Most patients under
treatment. Further
information not
provided
Patients consumed
less food, but
quality of their diet
is quite poor
Lower in patients Lower in patients Not reported Patients ate fewer
calories,
carbohydrate,
protein, folate,
sodium, alcohol but
more caffeine
Henderson
et al., 2010
46 chronic patients None 4 day dietary record
according to Reed
and Burke (1954)
31 clozapine-treated
patients and 15
risperidone-treated
patients
Clozapine patients
consumed more
saturated fats than
risperidone-treated
ones
Higher in patients
under clozapine
Not reported Not reported None
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Henderson
et al., 2011
35 chronic patients None 4 day dietary record
according to Reed
and Burke (1954)
35 patients under
clozapine: among
these, 19 received in
addition modaﬁnil,
whilst 16 received in
addition a placebo
Total caloric intake,
carbohydrate,
sucrose and
caffeine
consumption was
non-signiﬁcantly
lower in the
modaﬁnil group
Not reported Not reported Not reported Non- signiﬁcant
differences
McCreadie
et al., 1998
30 chronic patients 30 matched controls Food frequency
questionnaire
No info Patients consume
signiﬁcantly less
ﬁbre, retinol,
carotene, vitamin C,
vitamin E and
alcohol
Higher in patients Lower in patients Lower in patients None
McCreadie,
2003
102 chronic
patients
Data from general
population
Eating habits section
of the Scottish Health
Survey Questionnaire
No info Patients consumed
less fruit,
vegetables, milk,
potatoes and pulses
No differences Lower in patients,
especially in men
Lower in patients,
especially in men
None
Osborn et al.,
2007
74 chronic patients 148 controls DINE Patients under
treatment. Results
have been adjusted
for medication.
Further information
not provided
Patients eat
signiﬁcantly less
ﬁbre and low
saturated fat
Lower intake of low
saturated fat in
patients
Lower in patients Not reported None
Roick et al.,
2007
194 chronic
patients
Data from general
population
Dietary habits
sections of the
GNHIES 98
Most patients under
treatment. Further
information not
provided
Patients are less
likely to eat ﬁbre
and fruits
No differences Lower in patients Lower in patients Patients are less
likely to eat
reduced calorie
food
Saarni et al.,
2009
208 chronic
patients with
schizophrenia, with
affective or non-
affective pscychosis
Data from Health
2000 study
Eating habits
assessed through
a series of verbal
questions from the
Finnish Health
Examination Survey
No info The percentage of
healthiness of diet
was non-
signiﬁcantly lower
in the patients
group
No differences No differences Not assessed None
Strassnig et al.,
2003
146 chronic
patients
Data from general
population
A 24 h diet recall
using standardized
food models
No info Patients have
a worse diet, but
the percentages of
calories from
macronutrients are
not different from
healthy subjects
Higher in patients,
but the percentages
of calories from fat
are not different
from healthy
subjects
No differences No differences Increased caloric
intake in patients
Strassnig et al.,
2005b
146 chronic
patients
Data from general
population
A 24 h diet recall
using standardized
food models
No info Saturated and
polyunsaturated
fatty acid (PUFA)
intake was higher
in schizophrenia
patients than in
controls
Higher in patients Not reported Not reported None
Strassnig et al.,
2006
146 chronic
patients
Data from general
population
A 24 h diet recall
using standardized
food models
Patients under
treatment. Further
information not
provided
Caffeine
consumption and
smoking were not
correlated to diet
Not correlated with
caffeine or smoking
Not reported Not reported None
Suvisaari et al.,
2007
118 chronic
patients divided in
three groups
(patients with
schizophrenia, with
affective psychosis,
Data from Health
2000 study
Eating habits
assessed through
a series of verbal
questions from the
Finnish Health
Examination Survey
Patients under
treatment with three
classes of
antipsychotic drugs
(high potency, low
potency, atypical)
No differences
between the three
groups of patients
and between
patients and the
comparison group.
Not reported Not reported Not assessed None
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The diet was assessed retrospectively in most of the studies. Five
papers (Brown et al., 1999; Hepgul et al., 2011; Osborn et al., 2007;
Ryan et al., 2003, 2004) assessed eating habits of both cases and
controls using the DINE, a short structured questionnaire which
provides a brief initial assessment of intake of only total fat and
dietary ﬁbre; additional nutrients of interest, such as sugars, are not
included due to the need to keep the assessment tool short. The
DINE categorises respondents into high, medium or low intake of
ﬁbre, saturated fat and unsaturated fat. Similarly, other six papers
(Amani, 2007; Archie et al., 2007; Chuang et al., 2008; Gupta and
Craig, 2009; Roick et al., 2007; Samele et al., 2007) used short
food frequency questionnaires aimed at giving only a general
overview of fat and ﬁbre consumption. In contrast, another study
(McCreadie et al., 1998) obtained more detailed information on
dietary habits of patients (caloric intake, protein, fat, ﬁbre, retinol
and vitamins consumption) through a modiﬁed version of a known
food frequency questionnaire. Two studies (Strassnig et al., 2003,
2006) conducted a 24-h diet recall using standardized food models
to collect the nutritional information and estimate portion sizes. In
this 24-h recall method, nutritional values (ﬁbre, saturated fat,
mono and polyunsaturated fat and vitamins intake) were compared
to nutritional data for the general population of similar age from
NHANES III surveys (National Health and Nutrition Examination
Survey, Cycle III). A similar 24-h recall method was used by two
other papers (Ellingrod et al., 2011; Wallace and Tennant, 1998). Six
papers (Blouin et al., 2008; Gothelf et al., 2002; Henderson et al.,
2005, 2006, 2010, 2011) applied a perspective assessment of diet;
among these, four studies measured eating habits through a 4-day
dietary record, in which patients recorded their food and beverage
consumption for 4 consecutive days (Henderson et al., 2005, 2006,
2010, 2011). Nutritional variables included total energy intake, fat,
protein, carbohydrate, cholesterol, ﬁbre, sucrose, folate, calcium,
sodium, zinc, alcohol and caffeine; the ﬁndings were compared to
the general population using data matched for age, gender, and
ethnicity from the NHANES III surveys. One study (Blouin et al.,
2008) recorded food intake and food preferences of patients by
offering them a buffet-typemeal which provided a large diversity in
protein, lipid, and carbohydrate sources in order to facilitate the
detection of macronutrient preferences. After the record, the
authors calculated macronutrients intake by Canadian Nutrient File
(Canadian Nutrient File. Tape and User’s Guide. no. 58-42-1997E-
MRed. Health andWelfare Canada: Ottawa, 1997) or information on
food labels. Another paper (Gothelf et al., 2002) used a 2-day record
in which patients were allowed free choice of the type and amount
of food. All food products and beverages consumed bypatientswere
weighed before and after the meal and the total daily caloric intake,
as well as carbohydrate, fat, and protein contents, were calculated
from computerized food tables.
Finally, some authors (Arango et al., 2008; Bobes et al., 2010;
Fusar-Poli et al., 2009; Treuer et al., 2009) assessed the diet through
a series of simple verbal questions regarding fat, ﬁbre, carbohy-
drates, salt and alcohol consumption without applying a proper-
scientiﬁc-structured model.
3.2. Differences in dietary pattern between patients with
schizophrenia and controls
The most common ﬁnding was that patients with schizophrenia
were more likely to consume a diet poor in ﬁbre and fruit intake
(Brown et al., 1999; Fusar-Poli et al., 2009; Gupta and Craig, 2009;
Henderson et al., 2006; McCreadie et al., 1998; McCreadie, 2003;
Osborn et al., 2007; Roick et al., 2007; Ryan et al., 2004; Wallace
and Tennant, 1998) and rich in saturated fat (Amani, 2007; Archie
S. Dipasquale et al. / Journal of Psychiatric Research 47 (2013) 197e207 203et al., 2007; Brown et al., 1999; Henderson et al., 2010; Osborn et al.,
2007; Ryan et al., 2003, 2004; Strassnig et al., 2005b). A few studies
also reported a signiﬁcantly increased intake of calories (DeMyer
et al., 1968; Strassnig et al., 2003) and a low consumption of both
monounsaturated and polyunsaturated fatty acids (Henderson
et al., 2006). Five studies did not report any signiﬁcant difference
in the diet of patients with schizophrenia compared with healthy
subjects (Blouin et al., 2008; Henderson et al., 2005; Saarni et al.,
2009; Strassnig et al., 2003; Suvisaari et al., 2007) or with other
patients affected by depression or bipolar disorder (Chuang et al.,
2008).
3.3. Dietary pattern and metabolic abnormalities
Most papers assessed cardiovascular risk and unhealthy lifestyle
such as smoking, caffeine and alcohol consumption and poor
physical activity in patients with schizophrenia. Subjects with
a poor diet and an unhealthy lifestyle were more likely to be over-
weight or obese (Archie et al., 2007; Brown et al., 1999; Fusar-Poli
et al., 2009; Gupta and Craig, 2009; Henderson et al., 2006;
McCreadie, 2003; Strassnig et al., 2003), with high LDL-c (Fusar-Poli
et al., 2009; McCreadie, 2003; Osborn et al., 2007; Ryan et al., 2003)
and low HDL-c blood levels (McCreadie, 2003; Osborn et al., 2007),
along with increased fasting glucose (Arango et al., 2008; Fusar-Poli
et al., 2009). The cardiovascular risk was mainly measured with the
Framingham assessment, and patients showed a signiﬁcant
increased risk due to their unhealthy lifestyle (Bobes et al., 2010;
Fusar-Poli et al., 2009; Gupta and Craig, 2009; McCreadie, 2003;
Osborn et al., 2007).
3.4. Factors inﬂuencing dietary pattern in schizophrenia
Only few studies investigated which factors may inﬂuence the
diet of individuals with schizophrenia and the ﬁndings appear to be
inconsistent. Results from two studies suggest that the poor diet
associated with schizophrenia is inﬂuenced by socioeconomic
status (Roick et al., 2007; Samele et al., 2007); however, another
studywas not able to replicate this ﬁnding (Osborn et al., 2007). The
effects of gender and smoking status on diet revealed thatmen tend
to have a less healthy diet than women, eating signiﬁcantly less
fruit, vegetables, milk and pulses (McCreadie, 2003), or were less
likely to consume healthy foods in general and more likely to
consume alcohol (Roick et al., 2007). On the other hand, other
authors noted that female patients consumed more fat, carbohy-
drates and calories (Strassnig et al., 2003), less fruit, vegetables and
nuts (Amani, 2007), less ﬁbre and more fats (Archie et al., 2007).
Regarding smoking habits, a signiﬁcant difference in dietary
patterns was reported between smoking and non-smoking
patients, as non-smokers showed healthier eating habits than
smokers (Bobes et al., 2010; McCreadie, 2003). However, another
study did not ﬁnd any correlation between smoking and diet
(Strassnig et al., 2006). The link between stress and diet has
been only brieﬂy investigated in previous studies. Indeed, it is
acknowledged that the hypothalamicepituitaryeadrenal axis may
inﬂuence both metabolic parameters and dietary pattern. In
a preliminary study by our team, we found that ﬁrst-episode
psychosis patients with childhood sexual abuse had a less healthy
diet, as indicated by lower ﬁbre intake, than patients without
a history of abuse (Hepgul et al., 2011). As childhood trauma is also
linked to hypothalamicepituitaryeadrenal axis and immune acti-
vation, it is possible to hypothesise that the association between
stress and dietary patterns of ﬁrst-episode psychosis patients is
mediated by these biological systems. However, only two of the
reported studies investigated cortisol levels (Ryan et al., 2003,
2004), but these studies did not explore the correlation betweencortisol secretion and diet. None of the other papers provided
information about stress levels or the association between stress
and diet in these patients. Similarly, very little has been reported on
the inﬂuence of antipsychotic treatment on diet. Patients treated
with olanzapine showed an increased consumption of candy/sweet
food after six months of treatment (Treuer et al., 2009) or a signiﬁ-
cant increased caloric intake without any change of diet macronu-
trient composition after four weeks of treatment (Gothelf et al.,
2002). In a study which compared two groups of patients treated
with either clozapine or risperidone (Henderson et al., 2010),
clozapine-treated subjects had a signiﬁcantly higher intake of
saturated fat and protein, along with a lower ﬁbre and carbohy-
drates consumption than risperidone-treated individuals; both
groups of patients expressed higher fats consumption than what is
recommended by National Cholesterol Education Program (NCEP).
However, in another paper (Henderson et al., 2005) the same author
did not report any difference in dietary habits between quetiapine-
treated patients and olanzapine-treated patients. At the same time,
another author did not report any signiﬁcant difference in macro-
nutrient and caloric intake between patients treated with atypical
antipsychotics and patients treated with ﬁrst generation antipsy-
chotics (Ellingrod et al., 2011). Moreover, it has been reported a high
saturated fat and low ﬁbre intake in a sample of drug naïve patients
when compared with healthy controls; however, the same patients
did not show any signiﬁcant change in their dietary patterns after
six months of antipsychotic treatment (Ryan et al., 2004). In
agreement with these ﬁndings, another paper (Osborn et al., 2007)
showed that antipsychotic treatment did not inﬂuence diet, as
patients showed unhealthy dietary habits also after controlling for
medications. Finally, one study (Arango et al., 2008) compared the
dietary patterns of antipsychotic-treated patients with and without
the metabolic syndrome; surprisingly, the subjects affected by
metabolic syndrome were more likely to follow a healthier diet, to
control their salt intake and to avoid saturated fats and cholesterol
than those without metabolic syndrome.
4. Discussion
4.1. The inﬂuence of diet on metabolic abnormalities
Despite the authors used a number of different instruments for
the assessment of dietary habits, most of these studies agreed that
subjects with schizophrenia tend to have an unhealthy diet, rich in
saturated fats and poor in ﬁbre and fruit. These patients also show
a high caloric intake. As reported above, these dietary patterns are
known to be linked to the development of metabolic syndrome in
non-psychiatric individuals. Moreover, both high saturated fat
intake and low ﬁbre and fruit consumption are related with high
levels of inﬂammatory markers, especially tumour necrosis factor
(TNF)-alpha, interleukin (IL)-6 and C reactive protein (CRP), which
in turn may promote the development or the worsening of the
metabolic syndrome in genetically or metabolically predisposed
individuals (Esposito et al., 2004). This is particularly harmful in
patients with schizophrenia, who show an elevated oxidative stress
(Minutolo et al., 2012), high levels of pro-inﬂammatory cytokines
and several metabolic abnormalities, also at the onset of the illness
(Mondelli et al., 2011; Pennington et al., 2008; Ryan et al., 2003).
Despite these ﬁndings, in the studies we reviewed, the link
between poor diet and the metabolic abnormalities was not clearly
elucidated. Surprisingly, most papers did not explore the correla-
tion between diet and metabolic variables. Indeed, these studies
were more focused on investigating whether the lifestyle, the
metabolic parameters and the cardiovascular risk of people with
schizophrenia were actually different from those of healthy
subjects. However, it has been reported that higher saturated-fat
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proportionally associated with impaired glucose homeostasis
(Henderson et al., 2010); in particular, the consumption of satu-
rated fats was negatively correlated with disposition index (an
index of b-cell function) and glucose effectiveness (the net frac-
tional glucose clearance rate due to the increase in glucose, inde-
pendent of any increase in circulating insulin concentrations above
baseline). According to the authors, saturated fat might reduce both
glucose transporter (GLUT)-2 and glucokinase function and, at the
same time, induce oxidative stress and apoptosis of beta-cell mass,
thus compromising the insulin sensitivity. Another study (Ryan
et al., 2003) did not correlate diet and metabolic abnormalities;
however, the patient group showed a diet higher in saturated fat
along with lower fasting plasma levels of total cholesterol and LDL
cholesterol than the normal comparisons subject, thus suggesting
that poor diet is not associated with the development of metabolic
abnormalities. However, as most studies did not report a clear link
between diet and metabolic pattern, we have not been able to
clarify whether these metabolic abnormalities may be due to diet,
to other unhealthy lifestyle aspects, such as alcohol abuse, lack of
physical exercise, smoking, or to other factors, including stress or
antipsychotic treatment. Therefore, on the basis of the ﬁndings
from the studies reviewed and previous literature, we can only
suggest that a poor diet represents one of the factors involved in the
development of metabolic abnormalities. With this view, it is
important to clarify which factors may inﬂuence diet and conse-
quently have a role in the development of metabolic syndrome.
4.2. The role of smoking habits and socio-economic status in
abnormal dietary pattern in schizophrenia
Past studies in non-psychiatric patients reported that smokers,
when compared with non-smokers, presented a worse dietary
pattern (de Castro and Taylor, 2008); at the same time, it is well
known that people with schizophrenia have more than ﬁve times
the odds of current smoking than the general population (de Leon
and Diaz, 2005). In the studies we reviewed, smoking patients were
more likely to consume alcohol, caffeine, salt, saturated fats and
less likely to avoid the consumption of salt, saturated fats and to
follow a low-caloric diet (Bobes et al., 2010); they usually consumed
fewer portions of fruit and vegetables (McCreadie, 2003). In
contrast, another study (Strassnig et al., 2006) did not show any
inﬂuence of smoking habits on diet: however, none of these studies
discussed possible mechanisms behind the relationship between
smoking habits and diet in patients with schizophrenia, which are
still far from being properly clariﬁed.
It has been reported that the metabolic syndrome is associated
with lower socioeconomic status (Manuck et al., 2010) and subjects
with lower socioeconomic status are more likely to report
unhealthy eating habits (Darmon and Drewnowski, 2008). Indi-
viduals with schizophrenia usually belong to lower socioeconomic
classes (Agerbo et al., 2004; de Souza and Coutinho, 2006). In the
papers we reviewed, the importance of socioeconomic status may
have been underestimated as only few studies used a carefully
matched control group, or adjusted the outcomes for socioeco-
nomic status. Despite unemployment seems to predict a reduced
consumption of healthy groceries (Roick et al., 2007) and no
differences in dietary pattern were reported between patients and
controls after adjusting for unemployment and educational quali-
ﬁcation (Samele et al., 2007), some authors (Brown et al., 2000;
McCreadie, 2003) found that patients with schizophrenia have
a worse diet than the lowest social class of the general population
sample used as a comparison group. According to these authors,
their ﬁndings might be related to the presence of negative symp-
tomsof schizophrenia, like apathy,whichmaydecrease both energyand motivation, thus inducing the preference for easily obtainable
and less healthy food. Similarly, the negative symptoms of schizo-
phrenia may also worsen poor dietary patterns. These mixed ﬁnd-
ings make it difﬁcult to understand whether socioeconomic status
affects the diet of patients with schizophrenia.
4.3. The role of stress in the abnormal dietary pattern in
schizophrenia
Stress is thought to inﬂuence eating behaviour and this associ-
ation has been examined both in animals and humans (Dallman
et al., 2005; Morley et al., 1983). In humans, stress is more likely
to increase food intake, along with a high consumption of palatable
food, rich in saturated fat and sugar (Rutters et al., 2009). These
abnormalities may be related to an excessive activation of the
hypothalamicepituitaryeadrenal axis, which usually occurs in
subjects who may have a higher sensitivity to stress.
Patients with schizophrenia during the acute phase of illness
present a higher sensitivity to stress (Myin-Germeys and van Os,
2007), along with hyperactivity of the hypothalamicepituitarye
adrenal axis (Pariante, 2008), which in turn causes glucocorticoid
resistance (Mondelli et al., 2008; Pariante, 2009) and increased
circulating levels of adrenocorticotropic hormone (ACTH) and
cortisol.
Being more sensitive to stress has been associated with an
increased high palatable food intake, through a complex mecha-
nism involving elevated levels of ACTH, cortisol, leptin, insulin,
neuropeptide Y, and activation of the reward system (Adam and
Epel, 2007): this mechanism may explain the high saturated fat
consumption of patients with schizophrenia, at least at the onset of
illness.
However, in our review, we have not been able to test this
hypothesis as most studies have not assessed or reported cortisol
and stress levels. Two studies including drug naïve ﬁrst-episode
psychosis subjects (Ryan et al., 2003, 2004) have found both
hyper-cortisolemia and a signiﬁcant high intake of saturated fat,
but unfortunately these studies did not make any correlation
between these two variables. Moreover, it has been found a similar
poor dietary pattern in the same patients before and after six
months of antipsychotic treatment, although the patients showed
a decrease in cortisol levels after treatment (Ryan et al., 2004). This
ﬁnding suggests that high levels of stress and hyper-cortisolemia
may be more likely to inﬂuence diet only at onset, prior to the
implementation of the effects of antipsychotic treatment. Indeed, it
has also been reported that chronic patients, especially those on
antipsychotic treatment, may not express high levels of stress and/
or hyper-cortisolemia (Zhang et al., 2005) but, as revealed by the
outcomes of the studies reviewed in this paper, they may still
report poor dietary habits.
Thus, although stress is likely to affect the diet at the onset of
psychosis, it might have a less important role in the development or
in the maintenance of the abnormal dietary pattern in chronic
patients. In order to clarify this hypothesis, future studies should
take into account the inﬂuence of stress on diet in longitudinal
studies.
4.4. The role of antipsychotic treatment in abnormal dietary pattern
in schizophrenia
The mechanism by which antipsychotic medications increase
food intake has been explained by several alterations of neuro-
transmitters and hormonal pathways. The blockade of both sero-
tonin 2C (5HT2C) and the histamine 1 (H1) receptors (peculiar of
some second-generation antipsychotics such as olanzapine and
clozapine) is most frequently associated with metabolic risk
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the satiety control (Stahl et al., 2009), such as neuropeptide Y (NPY),
agouti-related peptide (AGRP), pro-opiomelanocortin (POMC) and,
especially, leptin (Porte et al., 2002). The blockade of histamine 1
(H1) receptors in the hypothalamus reverses the action of leptin on
satiety (Stahl et al., 2009), thus leading to further leptin secretion,
leptin resistance, increased appetite and food intake. At the same
time, the antagonism on serotonin 2C (5HT2C) may interfere with
leptin activity and may also cause increased NPY levels which in
turn stimulates food intake (Reynolds et al., 2006).
In addition to the effect on food intake, it is still unclear whether
these mechanisms inﬂuence also food choices. Because of the
scarce information on detailed medical histories, it is difﬁcult to
evaluate whether the antipsychotic treatment has inﬂuenced the
poor dietary habits reported in the studies reviewed in this paper.
Indeed, our review has focused especially on studies involving
chronic patients, with a long history of antipsychotic treatment. It
has been reported a less healthy dietary pattern in clozapine-
treated patients than risperidone-treated ones (Henderson et al.,
2010), an increased consumption of candy/sweet food in patients
after six months of treatment with olanzapine (Treuer et al., 2009)
and an enhanced caloric intake in olanzapine-treated patients after
four weeks of treatment, without any change of food choices
(Gothelf et al., 2002). In contrast, other authors (Ellingrod et al.,
2011; Henderson et al., 2005; Osborn et al., 2007; Ryan et al.,
2004) did not ﬁnd any signiﬁcant inﬂuence of antipsychotic treat-
ment on diet. However, these results seem to be in contrast with
what has been reported in the literature concerning the inﬂuence
of antipsychotic drugs on food intake (Basson et al., 2001). Future
studies should elucidate the inﬂuence of antipsychotic treatment
on diet of patients with schizophrenia and mechanisms underlying
this possible association.
5. Limitations
Although the literature has shown that stress, socioeconomic
status and antipsychotic treatment may affect diet, we have not
been able to assess whether these factors may be accountable for
the poor dietary habits of patients with schizophrenia, as the
results of the studies reviewed appear inconsistent. This inconsis-
tency is probably due to methodological issues. Indeed, most
studies involved chronic patients, without reporting stress levels
and antipsychotic treatment and without adjusting the results for
socioeconomic status. Few studies were also conducted on rela-
tively small samples of patients (less than 50) and using particular
selection criteria that might have partially inﬂuenced their ﬁnd-
ings. Moreover, only few studies used a carefully matched control
group and the diet was usually assessed retrospectively, often
through self-report questionnaire. Surprisingly, most papers did
not make any statistical correlation between diet and metabolic
abnormalities. To overcome some of these methodological issues,
future studies should focus on ﬁrst-episode psychosis patients,
include a carefully matched control group, report medication
history, and possibly assess stress, cortisol levels and socioeco-
nomic status.
6. Conclusions
To our knowledge, this is the ﬁrst review that has attempted to
analyse the key features that may inﬂuence the dietary habits of
patients with schizophrenia. Past reviews (Peet, 2004; Strassnig
et al., 2005a) have taken in account fewer studies and focussed
more on the metabolic abnormalities associated with unhealthy
lifestyle of these patients. Our ﬁndings conﬁrm those of past
reviews.We have found that peoplewith schizophrenia have a poordiet, mainly characterized by a high intake of saturated fat and
a low consumption of ﬁbre and fruit. Such diet is likely to increase
the risk of developing metabolic abnormalities, and may worsen
metabolic abnormalities induced by other factors (e.g. antipsy-
chotic treatment, hypothalamicepituitaryeadrenal axis hyperac-
tivity, low physical activity, smoking, and alcohol and substances
abuse). The diet and factors underlying poor dietary patterns may
represent an important therapeutic target to control metabolic
abnormalities in patients with schizophrenia.
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